Umbralisib (Ukoniq)
Jump to navigation
Jump to search
Mechanism of action
Phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ) and casein kinase-1ε inhibitor
Diseases for which it was used
Patient Drug Information
History of changes in FDA indication
- 2/5/2021: Accelerated approval for adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen. (Based on UNITY-NHL)
- 2/5/2021: Accelerated approval for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. (Based on UNITY-NHL)
- 6/1/2022: Withdrawn due to safety concerns. (Based on UNITY-CLL)
Also known as
- Code name: TGR-1202
- Brand name: Ukoniq